Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements-Reference-Cited by-同舟云学术

Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements

Published:2008-01-09 Issue:1 Volume:84 Page:111-118
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Hooker AC,Ten Tije AJ,Carducci MA,Weber J,Garrett-Mayer E,Gelderblom H,Mcguire WP,Verweij J,Karlsson MO,Baker SD

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference21 articles.

1. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

2. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver

3. Clinical Pharmacokinetics of Docetaxel

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial;BMC Complementary Medicine and Therapies;2024-09-04

2. A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients;Current Drug Metabolism;2024-08-16

3. Ameliorative delivery of docetaxel and curcumin using PEG decorated lipomers: A cutting-edge in-vitro/ in-vivo appraisal;Journal of Drug Delivery Science and Technology;2024-08

4. Hepatotoxicity of Anti-cancer Drugs;Interdisciplinary Cancer Research;2024

5. The Protective Effect of Curcumin on Hepatic Function in Cancer Patients Receiving Taxane-Based Chemotherapy: A Randomized Controlled Clinical Trial;MIDDLE EAST J CANCER;2023